Avantor (NYSE:AVTR) Reaches New 12-Month High – What’s Next?

Avantor, Inc. (NYSE:AVTR) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $15.99 and last traded at $15.8950, with a volume of 962209 shares. The stock had previously closed at $15.61.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Citigroup lifted their price objective on Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Wall Street Zen raised Avantor from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. TD Cowen reaffirmed a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th. Jefferies Financial Group raised shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 target price for the company in a research note on Wednesday, July 29th. Finally, Morgan Stanley raised their price target on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.47.

Avantor Stock Performance

The firm has a market cap of $10.78 billion, a price-to-earnings ratio of -18.97, a PEG ratio of 11.65 and a beta of 0.89. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average of $13.42 and a 200 day moving average of $10.28.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The company had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the previous year, the business earned $0.24 EPS. Avantor’s revenue for the quarter was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, equities research analysts expect that Avantor, Inc. will post 0.81 EPS for the current fiscal year.

Institutional Trading of Avantor

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Avantor during the 2nd quarter valued at $695,784,000. Engine Capital Management LP raised its stake in shares of Avantor by 65.8% in the 1st quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock valued at $155,082,000 after purchasing an additional 7,853,018 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in shares of Avantor in the 2nd quarter valued at about $195,386,000. Dimensional Fund Advisors LP lifted its position in shares of Avantor by 15.7% during the first quarter. Dimensional Fund Advisors LP now owns 16,894,649 shares of the company’s stock worth $132,443,000 after purchasing an additional 2,288,053 shares during the last quarter. Finally, Clarkston Capital Partners LLC grew its stake in Avantor by 0.6% in the fourth quarter. Clarkston Capital Partners LLC now owns 15,105,065 shares of the company’s stock worth $173,104,000 after purchasing an additional 84,740 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc (NYSE: AVTR) is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.

Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.

Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.